TY - JOUR
T1 - Head and neck paragangliomas
T2 - Genetic spectrum and clinical variability in 79 consecutive patients
AU - Piccini, Valentina
AU - Rapizzi, Elena
AU - Bacca, Alessandra
AU - Di Trapani, Giuseppe
AU - Pulli, Raffaele
AU - Giachè, Valentino
AU - Zampetti, Benedetta
AU - Lucci-Cordisco, Emanuela
AU - Canu, Letizia
AU - Corsini, Elisa
AU - Faggiano, Antongiulio
AU - Deiana, Luca
AU - Carrara, Davide
AU - Tantardini, Valeria
AU - Mariotti, Stefano
AU - Ambrosio, Maria Rosaria
AU - Zatelli, Maria Chiara
AU - Parenti, Gabriele
AU - Colao, Annamaria
AU - Pratesi, Carlo
AU - Bernini, Giampaolo
AU - Ercolino, Tonino
AU - Mannelli, Massimo
PY - 2012/4
Y1 - 2012/4
N2 - Head and neck paragangliomas (HNPGLs) are neural crest-derived tumors. In comparison with paragangliomas located in the abdomen and the chest, which are generally catecholamine secreting (sPGLs) and sympathetic in origin, HNPGLs are, in fact, parasympathetic in origin and are generally nonsecreting. Overall, 79 consecutive patients with HNPGL were examined for mutations in SDHA, SDHB, SDHC, SDHD, SDHAF2, VHL, MAX, and TMEM127 genes by PCR/sequencing. According to a detailed family history (FH) and clinical, laboratory (including metanephrines), and instrumental examinations, patients were divided into three groups: a) patients with a positive FH for HNPGL (index cases only), b) patients with a negative FH and multiple HNPGLs (synchronous or metachronous) or HNPGL associated with an sPGL, and c) patients with negative FH and single HNPGL. The ten patients in group a) proved to be SDHD mutation carriers. The 16 patients in group b) proved to be SDHD mutation carriers. Among the 53 patients in group c), ten presented with germ-line mutations (three SDHB, three SDHD, two VHL, and two SDHAF2). An sPGL was found at diagnosis or followed up in five patients (6.3%), all were SDHD mutation carriers. No SDHC, SDHA, MAX, and TMEM127 mutations were found. In SDHD mutation carriers, none of the patients affected by HNPGL associated with sPGL presented missense mutations. In conclusion, a positive FH or the presence of multiple HNPGLs is a strong predictor for germ-line mutations, which are also present in 18.8% of patients carefully classified as sporadic. The most frequently mutated gene so far is SDHD but others, including SDHB, SDHAF2, and VHL, may also be affected.
AB - Head and neck paragangliomas (HNPGLs) are neural crest-derived tumors. In comparison with paragangliomas located in the abdomen and the chest, which are generally catecholamine secreting (sPGLs) and sympathetic in origin, HNPGLs are, in fact, parasympathetic in origin and are generally nonsecreting. Overall, 79 consecutive patients with HNPGL were examined for mutations in SDHA, SDHB, SDHC, SDHD, SDHAF2, VHL, MAX, and TMEM127 genes by PCR/sequencing. According to a detailed family history (FH) and clinical, laboratory (including metanephrines), and instrumental examinations, patients were divided into three groups: a) patients with a positive FH for HNPGL (index cases only), b) patients with a negative FH and multiple HNPGLs (synchronous or metachronous) or HNPGL associated with an sPGL, and c) patients with negative FH and single HNPGL. The ten patients in group a) proved to be SDHD mutation carriers. The 16 patients in group b) proved to be SDHD mutation carriers. Among the 53 patients in group c), ten presented with germ-line mutations (three SDHB, three SDHD, two VHL, and two SDHAF2). An sPGL was found at diagnosis or followed up in five patients (6.3%), all were SDHD mutation carriers. No SDHC, SDHA, MAX, and TMEM127 mutations were found. In SDHD mutation carriers, none of the patients affected by HNPGL associated with sPGL presented missense mutations. In conclusion, a positive FH or the presence of multiple HNPGLs is a strong predictor for germ-line mutations, which are also present in 18.8% of patients carefully classified as sporadic. The most frequently mutated gene so far is SDHD but others, including SDHB, SDHAF2, and VHL, may also be affected.
UR - http://www.scopus.com/inward/record.url?scp=84860893439&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860893439&partnerID=8YFLogxK
U2 - 10.1530/ERC-11-0369
DO - 10.1530/ERC-11-0369
M3 - Article
C2 - 22241717
AN - SCOPUS:84860893439
VL - 19
SP - 149
EP - 155
JO - Endocrine-Related Cancer
JF - Endocrine-Related Cancer
SN - 1351-0088
IS - 2
ER -